BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service
clinical Contract Research Organization (CRO) that partners with biotech
companies to accelerate the development of advanced and novel therapeutics at
every phase, has today released a key research whitepaper entitled Antibody-drug
conjugates - Global Clinical Trial Landscape (https://bit.ly/3za9TFz).
Novotech's whitepaper examines how the antibody-drug conjugates (ADCs), a
revolutionary treatment approach, is reshaping cancer treatment. ADCs combine
the precision of monoclonal antibodies with potent cytotoxic payloads, promising
targeted drug delivery with minimal side effects.
The report explores the evolution of ADCs, detailing key milestones,
technological advancements, clinical successes, and highlights the significant
rise in ADC research and development, with over 150 compounds in clinical trials
and 15 FDA approved drugs. It also examines the promising commercial landscape,
showcasing the surge in investments and major pharmaceutical companies'
strategic interests in ADCs.
The Novotech research analyst team provides these expert reports every month,
completely free of charge. These reports offer up-to-date insights into global
clinical trial activity, revealing which regions experience the highest trial
volumes and the unique factors behind these trends. They tackle the potential
and real hurdles faced by biotech firms in specific therapeutic areas and
discuss future paths in treatments and investment trends.
Examining the clinical trial activity, the report found that from 2019 to 2023,
the ADC trial landscape experienced a substantial expansion, with close to
1,000 trials initiated worldwide. Asia-Pacific emerged as a frontrunner,
boasting a significant Compound Annual Growth Rate (CAGR) of 42.7%, underscoring
its pivotal role in advancing research and development in this space. North
America maintained steady growth at 25.2% CAGR, and Europe saw a moderate rise
with 13.6%. The United States and China led trial efforts, with contributions
from other countries such as Spain, Australia, and South Korea.
The report also notes a 30% increase in ADC-related publications over the last
three years, signaling growing commercial interest in translating academic
breakthroughs into tangible clinical applications. The United States leads in
both publications and patents, followed by China, Japan, and the United Kingdom.
Breast cancer and lymphoma dominated ADC research, with growth observed in
breast cancer and myeloma studies.
Key takeaways from the report include:

  * Phase II trials dominated the global ADC clinical trial landscape,
    representing over 50% of all trials, followed by Phase I and III with 27%
    and 22%. APAC leads in conducting trials across all phases, with its most
    significant contribution in Phase II.
  * Oncology emerged as the primary therapeutic focus, with over 97% (600) of

ADC trials, with Asia-Pacific leading in trial numbers at 40%, North America

    at 31%, Europe and ROW contributing 18% and 11% respectively.
  * A diverse landscape of targeted antigens and cytotoxic payloads, with
    tubulin inhibitors emerging as the predominant choice. The approval of
    trastuzumab deruxtecan (Enhertu) in 2019 highlighted a shift towards a
    broader range of ADC payloads, including topoisomerase I inhibitors and
    STING agonists.
  * With more than 340 companies actively engaged in ADC development, including
    industry giants like F. Hoffmann-La Roche and AbbVie, the landscape is
    witnessing a surge in interest and investment.
  * Over 200 ADCs are currently in development by companies including Merck,
    Seagen, Daiichi Sankyo, AbbVie, ADC Therapeutics, Byondis, CytomX, and

ImmunoGen, signaling a shift towards targeted cancer therapy, especially for prevalent cancers like breast and lung cancer.
This comprehensive resource is designed as a guide for healthcare professionals,
researchers, and organizations to accurately navigate the ADC clinical trial
landscape.
Download the report here (https://bit.ly/3za9TFz)
About Novotech Novotech-CRO.com (https://bit.ly/3RDfE4W)
Founded in 1997, Novotech is a global full-service clinical Contract Research
Organization (CRO) focused on partnering with biotech companies to accelerate
the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received
numerous prestigious awards, including the CRO Leadership Award 2023, the Asia
Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific
Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories,
Phase I facilities, drug development consulting, regulatory expertise, and has
experience with over 5,000 clinical projects, including Phase I to Phase IV
clinical trials and bioequivalence studies. With a presence in 34 office
locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member
visit https://bit.ly/3RDfE4W
An infographic accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ab1afd7f-461a-4e83-baf7-
27440c30e1a5
Â